Literature DB >> 17261497

Aggressive natural killer cell leukemia: report of a Chinese series and review of the literature.

John Ryder1, Xiaoqin Wang, Liming Bao, Sherilyn A Gross, Fu Hua, Richard D Irons.   

Abstract

Aggressive natural killer cell leukemia (ANKL) is a rare Epstein-Barr virus (EBV)-associated fulminating disease that is widely disseminated at diagnosis. Because of its typically extranodal presentation, differing degrees of NK cell involvement, and varying bone marrow pathology, ANKL can be confused with a reactive process. These features, coupled with a rapidly fatal course, have hampered systematic study of the pathogenesis of ANKL. Nine cases of ANKL were diagnosed and characterized by a single laboratory over a 2-year period. Constant features at presentation included disseminated disease, high fever, bone marrow involvement, and a high lactate dehydrogenase index. All cases were positive for EBV early region protein and negative for latent membrane protein 1, and all had a germline T-cell receptor gene configuration. Peripheral blood counts were variable, with severe thrombocytopenia being the most frequently encountered abnormality (7 of 9 cases). Hematophagocytosis, dyserythropoiesis, and stromal degeneration were the most frequent findings in the bone marrow. Neoplastic cells in the bone marrow were consistently CD2+, CD56+, CD45+, CD34-, CD117-, CD4-, and surface CD3-. Most cases were HLA-DR+ (8/9) and CD8- (8/9). Complex clonal cytogenetic abnormalities were found in 8 of 9 cases. Because of its aggressive course, rapid and accurate diagnosis of ANKL is essential for a better understanding of the etiology, pathogenesis, and treatment of the disease.

Entities:  

Mesh:

Year:  2007        PMID: 17261497     DOI: 10.1532/IJH97.A10612

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  52 in total

Review 1.  Extranodal peripheral T-cell and NK-cell neoplasms.

Authors:  E S Jaffe; L Krenacs; S Kumar; D W Kingma; M Raffeld
Journal:  Am J Clin Pathol       Date:  1999-01       Impact factor: 2.493

2.  TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).

Authors:  J Yodoi; K Teshigawara; T Nikaido; K Fukui; T Noma; T Honjo; M Takigawa; M Sasaki; N Minato; M Tsudo
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

3.  A novel natural killer cell line (KHYG-1) from a patient with aggressive natural killer cell leukemia carrying a p53 point mutation.

Authors:  M Yagita; C L Huang; H Umehara; Y Matsuo; R Tabata; M Miyake; Y Konaka; K Takatsuki
Journal:  Leukemia       Date:  2000-05       Impact factor: 11.528

4.  Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations.

Authors:  L L Siu; K F Wong; J K Chan; Y L Kwong
Journal:  Am J Pathol       Date:  1999-11       Impact factor: 4.307

5.  CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA.

Authors:  K Kawa-Ha; S Ishihara; T Ninomiya; K Yumura-Yagi; J Hara; F Murayama; A Tawa; K Hirai
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

6.  Hemophagocytosis as a para-neoplastic syndrome in NK cell leukemia.

Authors:  Y Kobayashi; S Uehara; K Inamori; R Shirato; K Ozawa; J Sklar; S Asano
Journal:  Int J Hematol       Date:  1996-08       Impact factor: 2.490

7.  Epstein-Barr virus-associated natural killer-large granular lymphocyte leukemia.

Authors:  A B Gelb; M van de Rijn; D P Regula; J P Cornbleet; O W Kamel; D S Horoupian; M L Cleary; R A Warnke
Journal:  Hum Pathol       Date:  1994-09       Impact factor: 3.466

8.  Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

Authors:  M J Robertson; K J Cochran; C Cameron; J M Le; R Tantravahi; J Ritz
Journal:  Exp Hematol       Date:  1996-02       Impact factor: 3.084

9.  Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.

Authors:  L A Fernandez; B Pope; C Lee; E Zayed
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

10.  Lymphoproliferative disorder of granular lymphocytes: nine cases including one with features of CD56 (NKH1)-positive aggressive natural killer cell lymphoma.

Authors:  G E Nichols; D E Normansell; M E Williams
Journal:  Mod Pathol       Date:  1994-10       Impact factor: 7.842

View more
  19 in total

1.  Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T-cell and natural killer-cell lymphomas.

Authors:  Andrei R Shustov; Theodore A Gooley; Brenda M Sandmaier; Judith Shizuru; Mohamed L Sorror; Firoozeh Sahebi; Peter McSweeney; Dietger Niederwieser; Benedetto Bruno; Rainer Storb; David G Maloney
Journal:  Br J Haematol       Date:  2010-05-09       Impact factor: 6.998

2.  A rare case of co-existent aggressive natural killer cell and acute monocytic leukemia with cytomegalovirus infection.

Authors:  Jian Huang; Wanmao Ni; Lei Wang; Wenjing Zhou; Jie Jin
Journal:  Int J Hematol       Date:  2008-04-26       Impact factor: 2.490

Review 3.  The legacy of the F344 rat as a cancer bioassay model (a retrospective summary of three common F344 rat neoplasms).

Authors:  Robert R Maronpot; Abraham Nyska; Jennifer E Foreman; Yuval Ramot
Journal:  Crit Rev Toxicol       Date:  2016-06-09       Impact factor: 5.635

4.  Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.

Authors:  Fumihiro Ishida; Young Hyeh Ko; Won Seog Kim; Junji Suzumiya; Yasushi Isobe; Kazuo Oshimi; Shigeo Nakamura; Ritsuro Suzuki
Journal:  Cancer Sci       Date:  2012-03-23       Impact factor: 6.716

Review 5.  Natural killer cell neoplasm: biology and pathology.

Authors:  Maria Francisca Ham; Young-Hyeh Ko
Journal:  Int J Hematol       Date:  2010-12-07       Impact factor: 2.490

6.  Achievement of disease control with donor-derived EB virus-specific cytotoxic T cells after allogeneic peripheral blood stem cell transplantation for aggressive NK-cell leukemia.

Authors:  Shojiro Haji; Motoaki Shiratsuchi; Takamitsu Matsushima; Akiko Takamatsu; Mariko Tsuda; Yasuhiro Tsukamoto; Emi Tanaka; Hirofumi Ohno; Eriko Fujioka; Yuriko Ishikawa; Ken-Ichi Imadome; Yoshihiro Ogawa
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

7.  EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.

Authors:  Juehua Gao; Amir Behdad; Peng Ji; Kristy L Wolniak; Olga Frankfurt; Yi-Hua Chen
Journal:  Mod Pathol       Date:  2017-05-26       Impact factor: 7.842

8.  Somatic mutations in KMT2D and TET2 associated with worse prognosis in Epstein-Barr virus-associated T or natural killer-cell lymphoproliferative disorders.

Authors:  Li-Min Gao; Sha Zhao; Wen-Yan Zhang; Mi Wang; Hui-Fang Li; Anle Lizaso; Wei-Ping Liu
Journal:  Cancer Biol Ther       Date:  2019-07-16       Impact factor: 4.742

9.  Favorable outcome in a child with EBV-negative aggressive NK cell leukemia.

Authors:  Jeong A Park; Kyung Ran Jun; So Hyun Nam; Thad T Ghim
Journal:  Int J Hematol       Date:  2013-04-04       Impact factor: 2.490

10.  A prospective study of 728 cases of non-Hodgkin lymphoma from a single laboratory in Shanghai, China.

Authors:  Sherilyn A Gross; Xiongzeng Zhu; Liming Bao; John Ryder; Anh Le; Yan Chen; Xiao Qin Wang; Richard D Irons
Journal:  Int J Hematol       Date:  2008-07-23       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.